When making a dx of neuropsychiatric SLE I order labs AND @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020

MTX in GCA (+/- TCZ): can GiACTA data provide insights? MTX didn't add anything from data provided, but channelling bias a definite issue (note PNL numerically higher in non-MTX). MTX as adjunct/cover post-TCZ? We'll need to test for it properly FRI0220 #EULAR2020 @RheumNow https://t.co/BCsEKqqaMh

I've heard people say FDG uptake on PET/CT in PMR/GCA is just a correlate of systemic inflamm. Look at the uptake intensity (SUVmax) vs inflamm markers in n=65 PET/CT in GCA. There's no pattern whatsoever. Not just an expensive ESR! @FreemanHospital SAT0272 #EULAR2020 @RheumNow https://t.co/D4xAZC7KmO

To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers. Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes! EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV

Is there subclinical GCA in PMR pts? 50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular uptake, of which 10 had no GCA symptoms at all. Is PMR sometimes just the tip of the GCA iceberg? Do the aSx USS+ pts get GCA Sx eventually? Bonn SAT0254 #EULAR2020 @RheumNow https://t.co/UmsixY29Qh

GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail. Large Israeli database says there are links (EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why? OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah

#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs

#EULAR2020 Most innovative! Vaccination with IFNa-kinoid to induce anti-IFNa antibodies to treat SLE (results of phase IIb trial). https://t.co/rM0z23ieQW @RheumNow https://t.co/OYMdDZl6sb

• https://ard.bmj.com/content/79/3/347

#EULAR2020 OP0160 Prospective study of Hopkins Lupus Cohort: HCQ blood levels can predict risk for thrombotic events in SLE. Dr. M Petri advocates this is another reason for monitoring HCQ whole blood levels. Goal HCQ whole blood level should be 1000-1500 ng/mL @rheumnow https://t.co/mM6jsJ2Qmf

#EULAR2020 OP0163 Updated Lupus Nephritis EULAR/ERA-EDTA Recc: 1. T2T:⬇️proteinuria 50%@6 mo,UPCR<700 mg/g@12mo 2. Class III/IV:MMF, Euro-CYP; MMF+CNI 3. goal pred < 7.5 mg/day@6 mo 4.Class IV: MMF, CNI, CTX 5. Maintain w/MMF, AZP 6.🔃renal Bx w/refract. dz @RheumNow https://t.co/tGaSIDG1ji

#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF

#EULAR2020 panel on #COVID19 spec. situatns: 1. German regtry: very few preg rheum pts w/CV19; cases mild. 2. No info how CV19 affects APS 3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop 4. Most rheum pts w/CV19 good prognosis @rheumnow https://t.co/LQVdzJKCgu

#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h

New #therapeutic strategies in #SLE management #EULAR2020 https://t.co/dhvTKd4EGB

Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw

• https://twitter.com/kdao2011/status/1268532437275025409